PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well PXD101 works in treating patients with relapsed or
refractory aggressive B-cell non-Hodgkin's lymphoma. PXD101 may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the cancer.